1 Study Coverage
1.1 Prophylactic HIV Drug Product Introduction
1.2 Market by Type
1.2.1 Global Prophylactic HIV Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
1.2.3 Integrase Inhibitor
1.3 Market by Application
1.3.1 Global Prophylactic HIV Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Prophylactic HIV Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Prophylactic HIV Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Prophylactic HIV Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Prophylactic HIV Drug Sales by Region
2.4.1 Global Prophylactic HIV Drug Sales by Region (2017-2022)
2.4.2 Global Sales Prophylactic HIV Drug by Region (2023-2028)
2.5 Global Prophylactic HIV Drug Revenue by Region
2.5.1 Global Prophylactic HIV Drug Revenue by Region (2017-2022)
2.5.2 Global Prophylactic HIV Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Prophylactic HIV Drug Sales by Manufacturers
3.1.1 Global Top Prophylactic HIV Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Prophylactic HIV Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Prophylactic HIV Drug in 2021
3.2 Global Prophylactic HIV Drug Revenue by Manufacturers
3.2.1 Global Prophylactic HIV Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Prophylactic HIV Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Prophylactic HIV Drug Revenue in 2021
3.3 Global Prophylactic HIV Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Prophylactic HIV Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Prophylactic HIV Drug Sales by Type
4.1.1 Global Prophylactic HIV Drug Historical Sales by Type (2017-2022)
4.1.2 Global Prophylactic HIV Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
4.2 Global Prophylactic HIV Drug Revenue by Type
4.2.1 Global Prophylactic HIV Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Prophylactic HIV Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
4.3 Global Prophylactic HIV Drug Price by Type
4.3.1 Global Prophylactic HIV Drug Price by Type (2017-2022)
4.3.2 Global Prophylactic HIV Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Prophylactic HIV Drug Sales by Application
5.1.1 Global Prophylactic HIV Drug Historical Sales by Application (2017-2022)
5.1.2 Global Prophylactic HIV Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
5.2 Global Prophylactic HIV Drug Revenue by Application
5.2.1 Global Prophylactic HIV Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Prophylactic HIV Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
5.3 Global Prophylactic HIV Drug Price by Application
5.3.1 Global Prophylactic HIV Drug Price by Application (2017-2022)
5.3.2 Global Prophylactic HIV Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Prophylactic HIV Drug Market Size by Type
6.1.1 North America Prophylactic HIV Drug Sales by Type (2017-2028)
6.1.2 North America Prophylactic HIV Drug Revenue by Type (2017-2028)
6.2 North America Prophylactic HIV Drug Market Size by Application
6.2.1 North America Prophylactic HIV Drug Sales by Application (2017-2028)
6.2.2 North America Prophylactic HIV Drug Revenue by Application (2017-2028)
6.3 North America Prophylactic HIV Drug Market Size by Country
6.3.1 North America Prophylactic HIV Drug Sales by Country (2017-2028)
6.3.2 North America Prophylactic HIV Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Prophylactic HIV Drug Market Size by Type
7.1.1 Europe Prophylactic HIV Drug Sales by Type (2017-2028)
7.1.2 Europe Prophylactic HIV Drug Revenue by Type (2017-2028)
7.2 Europe Prophylactic HIV Drug Market Size by Application
7.2.1 Europe Prophylactic HIV Drug Sales by Application (2017-2028)
7.2.2 Europe Prophylactic HIV Drug Revenue by Application (2017-2028)
7.3 Europe Prophylactic HIV Drug Market Size by Country
7.3.1 Europe Prophylactic HIV Drug Sales by Country (2017-2028)
7.3.2 Europe Prophylactic HIV Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Prophylactic HIV Drug Market Size by Type
8.1.1 Asia Pacific Prophylactic HIV Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Prophylactic HIV Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Prophylactic HIV Drug Market Size by Application
8.2.1 Asia Pacific Prophylactic HIV Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Prophylactic HIV Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Prophylactic HIV Drug Market Size by Region
8.3.1 Asia Pacific Prophylactic HIV Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Prophylactic HIV Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Prophylactic HIV Drug Market Size by Type
9.1.1 Latin America Prophylactic HIV Drug Sales by Type (2017-2028)
9.1.2 Latin America Prophylactic HIV Drug Revenue by Type (2017-2028)
9.2 Latin America Prophylactic HIV Drug Market Size by Application
9.2.1 Latin America Prophylactic HIV Drug Sales by Application (2017-2028)
9.2.2 Latin America Prophylactic HIV Drug Revenue by Application (2017-2028)
9.3 Latin America Prophylactic HIV Drug Market Size by Country
9.3.1 Latin America Prophylactic HIV Drug Sales by Country (2017-2028)
9.3.2 Latin America Prophylactic HIV Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Prophylactic HIV Drug Market Size by Type
10.1.1 Middle East and Africa Prophylactic HIV Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Prophylactic HIV Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Prophylactic HIV Drug Market Size by Application
10.2.1 Middle East and Africa Prophylactic HIV Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Prophylactic HIV Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Prophylactic HIV Drug Market Size by Country
10.3.1 Middle East and Africa Prophylactic HIV Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Prophylactic HIV Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Corporation Information
11.1.2 Gilead Sciences Overview
11.1.3 Gilead Sciences Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Gilead Sciences Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Gilead Sciences Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
11.3 Mylan
11.3.1 Mylan Corporation Information
11.3.2 Mylan Overview
11.3.3 Mylan Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Mylan Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Mylan Recent Developments
11.4 Cipla
11.4.1 Cipla Corporation Information
11.4.2 Cipla Overview
11.4.3 Cipla Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Cipla Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cipla Recent Developments
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Corporation Information
11.5.2 Bristol-Myers Squibb Overview
11.5.3 Bristol-Myers Squibb Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Bristol-Myers Squibb Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Bristol-Myers Squibb Recent Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Overview
11.6.3 Roche Prophylactic HIV Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Roche Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Roche Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Prophylactic HIV Drug Industry Chain Analysis
12.2 Prophylactic HIV Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Prophylactic HIV Drug Production Mode & Process
12.4 Prophylactic HIV Drug Sales and Marketing
12.4.1 Prophylactic HIV Drug Sales Channels
12.4.2 Prophylactic HIV Drug Distributors
12.5 Prophylactic HIV Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Prophylactic HIV Drug Industry Trends
13.2 Prophylactic HIV Drug Market Drivers
13.3 Prophylactic HIV Drug Market Challenges
13.4 Prophylactic HIV Drug Market Restraints
14 Key Findings in The Global Prophylactic HIV Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Prophylactic HIV Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
Table 3. Major Manufacturers of Integrase Inhibitor
Table 4. Global Prophylactic HIV Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Prophylactic HIV Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Prophylactic HIV Drug Sales by Region (2017-2022) & (K Units)
Table 7. Global Prophylactic HIV Drug Sales Market Share by Region (2017-2022)
Table 8. Global Prophylactic HIV Drug Sales by Region (2023-2028) & (K Units)
Table 9. Global Prophylactic HIV Drug Sales Market Share by Region (2023-2028)
Table 10. Global Prophylactic HIV Drug Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Prophylactic HIV Drug Revenue Market Share by Region (2017-2022)
Table 12. Global Prophylactic HIV Drug Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Prophylactic HIV Drug Revenue Market Share by Region (2023-2028)
Table 14. Global Prophylactic HIV Drug Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Prophylactic HIV Drug Sales Share by Manufacturers (2017-2022)
Table 16. Global Prophylactic HIV Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Prophylactic HIV Drug Revenue Share by Manufacturers (2017-2022)
Table 18. Prophylactic HIV Drug Price by Manufacturers (2017-2022) &(USD/Unit)
Table 19. Global Prophylactic HIV Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Prophylactic HIV Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prophylactic HIV Drug as of 2021)
Table 21. Prophylactic HIV Drug Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Prophylactic HIV Drug Product Offered
Table 23. Date of Manufacturers Enter into Prophylactic HIV Drug Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Prophylactic HIV Drug Sales by Type (2017-2022) & (K Units)
Table 26. Global Prophylactic HIV Drug Sales by Type (2023-2028) & (K Units)
Table 27. Global Prophylactic HIV Drug Sales Share by Type (2017-2022)
Table 28. Global Prophylactic HIV Drug Sales Share by Type (2023-2028)
Table 29. Global Prophylactic HIV Drug Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Prophylactic HIV Drug Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Prophylactic HIV Drug Revenue Share by Type (2017-2022)
Table 32. Global Prophylactic HIV Drug Revenue Share by Type (2023-2028)
Table 33. Prophylactic HIV Drug Price by Type (2017-2022) & (USD/Unit)
Table 34. Global Prophylactic HIV Drug Price Forecast by Type (2023-2028) & (USD/Unit)
Table 35. Global Prophylactic HIV Drug Sales by Application (2017-2022) & (K Units)
Table 36. Global Prophylactic HIV Drug Sales by Application (2023-2028) & (K Units)
Table 37. Global Prophylactic HIV Drug Sales Share by Application (2017-2022)
Table 38. Global Prophylactic HIV Drug Sales Share by Application (2023-2028)
Table 39. Global Prophylactic HIV Drug Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Prophylactic HIV Drug Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Prophylactic HIV Drug Revenue Share by Application (2017-2022)
Table 42. Global Prophylactic HIV Drug Revenue Share by Application (2023-2028)
Table 43. Prophylactic HIV Drug Price by Application (2017-2022) & (USD/Unit)
Table 44. Global Prophylactic HIV Drug Price Forecast by Application (2023-2028) & (USD/Unit)
Table 45. North America Prophylactic HIV Drug Sales by Type (2017-2022) & (K Units)
Table 46. North America Prophylactic HIV Drug Sales by Type (2023-2028) & (K Units)
Table 47. North America Prophylactic HIV Drug Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Prophylactic HIV Drug Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Prophylactic HIV Drug Sales by Application (2017-2022) & (K Units)
Table 50. North America Prophylactic HIV Drug Sales by Application (2023-2028) & (K Units)
Table 51. North America Prophylactic HIV Drug Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Prophylactic HIV Drug Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Prophylactic HIV Drug Sales by Country (2017-2022) & (K Units)
Table 54. North America Prophylactic HIV Drug Sales by Country (2023-2028) & (K Units)
Table 55. North America Prophylactic HIV Drug Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Prophylactic HIV Drug Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Prophylactic HIV Drug Sales by Type (2017-2022) & (K Units)
Table 58. Europe Prophylactic HIV Drug Sales by Type (2023-2028) & (K Units)
Table 59. Europe Prophylactic HIV Drug Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Prophylactic HIV Drug Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Prophylactic HIV Drug Sales by Application (2017-2022) & (K Units)
Table 62. Europe Prophylactic HIV Drug Sales by Application (2023-2028) & (K Units)
Table 63. Europe Prophylactic HIV Drug Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Prophylactic HIV Drug Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Prophylactic HIV Drug Sales by Country (2017-2022) & (K Units)
Table 66. Europe Prophylactic HIV Drug Sales by Country (2023-2028) & (K Units)
Table 67. Europe Prophylactic HIV Drug Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Prophylactic HIV Drug Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Prophylactic HIV Drug Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Prophylactic HIV Drug Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Prophylactic HIV Drug Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Prophylactic HIV Drug Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Prophylactic HIV Drug Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Prophylactic HIV Drug Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Prophylactic HIV Drug Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Prophylactic HIV Drug Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Prophylactic HIV Drug Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Prophylactic HIV Drug Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Prophylactic HIV Drug Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Prophylactic HIV Drug Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Prophylactic HIV Drug Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Prophylactic HIV Drug Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Prophylactic HIV Drug Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Prophylactic HIV Drug Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Prophylactic HIV Drug Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Prophylactic HIV Drug Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Prophylactic HIV Drug Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Prophylactic HIV Drug Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Prophylactic HIV Drug Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Prophylactic HIV Drug Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Prophylactic HIV Drug Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Prophylactic HIV Drug Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Prophylactic HIV Drug Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Prophylactic HIV Drug Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Prophylactic HIV Drug Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Prophylactic HIV Drug Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Prophylactic HIV Drug Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Prophylactic HIV Drug Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Prophylactic HIV Drug Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Prophylactic HIV Drug Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Prophylactic HIV Drug Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Prophylactic HIV Drug Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Prophylactic HIV Drug Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Prophylactic HIV Drug Revenue by Country (2023-2028) & (US$ Million)
Table 105. Gilead Sciences Corporation Information
Table 106. Gilead Sciences Description and Major Businesses
Table 107. Gilead Sciences Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 108. Gilead Sciences Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Gilead Sciences Recent Developments
Table 110. Merck Corporation Information
Table 111. Merck Description and Major Businesses
Table 112. Merck Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 113. Merck Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Merck Recent Developments
Table 115. Mylan Corporation Information
Table 116. Mylan Description and Major Businesses
Table 117. Mylan Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 118. Mylan Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Mylan Recent Developments
Table 120. Cipla Corporation Information
Table 121. Cipla Description and Major Businesses
Table 122. Cipla Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 123. Cipla Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Cipla Recent Developments
Table 125. Bristol-Myers Squibb Corporation Information
Table 126. Bristol-Myers Squibb Description and Major Businesses
Table 127. Bristol-Myers Squibb Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 128. Bristol-Myers Squibb Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Bristol-Myers Squibb Recent Developments
Table 130. Roche Corporation Information
Table 131. Roche Description and Major Businesses
Table 132. Roche Prophylactic HIV Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 133. Roche Prophylactic HIV Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Roche Recent Developments
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Prophylactic HIV Drug Distributors List
Table 138. Prophylactic HIV Drug Customers List
Table 139. Prophylactic HIV Drug Market Trends
Table 140. Prophylactic HIV Drug Market Drivers
Table 141. Prophylactic HIV Drug Market Challenges
Table 142. Prophylactic HIV Drug Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Prophylactic HIV Drug Product Picture
Figure 3. Global Prophylactic HIV Drug Market Share by Type in 2021 & 2028
Figure 3. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI) Product Picture
Figure 4. Integrase Inhibitor Product Picture
Figure 5. Global Prophylactic HIV Drug Market Share by Application in 2021 & 2028
Figure 6. Hospital Pharmacy
Figure 7. Retail Pharmacy
Figure 8. Online Pharmacy
Figure 9. Prophylactic HIV Drug Report Years Considered
Figure 10. Global Prophylactic HIV Drug Sales 2017-2028 (K Units)
Figure 11. Global Prophylactic HIV Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global Prophylactic HIV Drug Revenue 2017-2028 (US$ Million)
Figure 13. Global Prophylactic HIV Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 14. Global Prophylactic HIV Drug Sales Market Share by Region (2017-2022)
Figure 15. Global Prophylactic HIV Drug Sales Market Share by Region (2023-2028)
Figure 16. North America Prophylactic HIV Drug Sales YoY (2017-2028) & (K Units)
Figure 17. North America Prophylactic HIV Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 18. Europe Prophylactic HIV Drug Sales YoY (2017-2028) & (K Units)
Figure 19. Europe Prophylactic HIV Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Asia-Pacific Prophylactic HIV Drug Sales YoY (2017-2028) & (K Units)
Figure 21. Asia-Pacific Prophylactic HIV Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Latin America Prophylactic HIV Drug Sales YoY (2017-2028) & (K Units)
Figure 23. Latin America Prophylactic HIV Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Middle East & Africa Prophylactic HIV Drug Sales YoY (2017-2028) & (K Units)
Figure 25. Middle East & Africa Prophylactic HIV Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. The Prophylactic HIV Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 27. The Top 5 and 10 Largest Manufacturers of Prophylactic HIV Drug in the World: Market Share by Prophylactic HIV Drug Revenue in 2021
Figure 28. Global Prophylactic HIV Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 29. Global Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
Figure 30. Global Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
Figure 31. Global Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
Figure 32. Global Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
Figure 33. North America Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
Figure 34. North America Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
Figure 35. North America Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
Figure 36. North America Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
Figure 37. North America Prophylactic HIV Drug Sales Share by Country (2017-2028)
Figure 38. North America Prophylactic HIV Drug Revenue Share by Country (2017-2028)
Figure 39. U.S. Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 40. Canada Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 41. Europe Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
Figure 42. Europe Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
Figure 43. Europe Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
Figure 44. Europe Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
Figure 45. Europe Prophylactic HIV Drug Sales Share by Country (2017-2028)
Figure 46. Europe Prophylactic HIV Drug Revenue Share by Country (2017-2028)
Figure 47. Germany Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 48. France Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 49. U.K. Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 50. Italy Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 51. Russia Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 52. Asia Pacific Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
Figure 53. Asia Pacific Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
Figure 54. Asia Pacific Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
Figure 55. Asia Pacific Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
Figure 56. Asia Pacific Prophylactic HIV Drug Sales Share by Region (2017-2028)
Figure 57. Asia Pacific Prophylactic HIV Drug Revenue Share by Region (2017-2028)
Figure 58. China Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 59. Japan Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 60. South Korea Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 61. India Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 62. Australia Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 63. Taiwan Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 64. Indonesia Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 65. Thailand Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Malaysia Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Philippines Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
Figure 69. Latin America Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
Figure 71. Latin America Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Prophylactic HIV Drug Sales Share by Country (2017-2028)
Figure 73. Latin America Prophylactic HIV Drug Revenue Share by Country (2017-2028)
Figure 74. Mexico Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Prophylactic HIV Drug Sales Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Prophylactic HIV Drug Revenue Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Prophylactic HIV Drug Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Prophylactic HIV Drug Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Prophylactic HIV Drug Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Prophylactic HIV Drug Revenue Share by Country (2017-2028)
Figure 83. Turkey Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 85. U.A.E Prophylactic HIV Drug Revenue (2017-2028) & (US$ Million)
Figure 86. Prophylactic HIV Drug Value Chain
Figure 87. Prophylactic HIV Drug Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed
